Dr. Temitope  Foster  Md, Mscr image

Dr. Temitope Foster Md, Mscr

49 Jesse Hill Jr Dr Se Rm437
Atlanta GA 30303
404 781-1682
Medical School: Mount Sinai School Of Medicine Of City University Of New York - 2002
Accepts Medicare: Yes
Participates In eRX: No
Participates In PQRS: No
Participates In EHR: No
License #:
NPI: 1356538615
Taxonomy Codes:
207R00000X 207RG0100X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy


Dr. Temitope Foster is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:45385 Description:Lesion removal colonoscopy Average Price:$592.00 Average Price Allowed
By Medicare:
HCPCS Code:45380 Description:Colonoscopy and biopsy Average Price:$499.00 Average Price Allowed
By Medicare:
HCPCS Code:45378 Description:Diagnostic colonoscopy Average Price:$422.00 Average Price Allowed
By Medicare:
HCPCS Code:G0121 Description:Colon ca scrn not hi rsk ind Average Price:$419.00 Average Price Allowed
By Medicare:
HCPCS Code:43239 Description:Upper gi endoscopy biopsy Average Price:$318.00 Average Price Allowed
By Medicare:
HCPCS Code:43235 Description:Uppr gi endoscopy diagnosis Average Price:$268.00 Average Price Allowed
By Medicare:
HCPCS Code:99222 Description:Initial hospital care Average Price:$222.00 Average Price Allowed
By Medicare:

HCPCS Code Definitions

Colonoscopy, flexible, proximal to splenic flexure; diagnostic, with or without collection of specimen(s) by brushing or washing, with or without colon decompression (separate procedure)
Esophagogastroduodenoscopy, flexible, transoral; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple
Colonoscopy, flexible, proximal to splenic flexure; with biopsy, single or multiple
Colonoscopy, flexible, proximal to splenic flexure; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique
Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of moderate severity. Typically, 50 minutes are spent at the bedside and on the patient's hospital floor or unit.
Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found


Doctor Name
Cardiovascular Disease (Cardiology)
Diagnostic Radiology
Physical Medicine And Rehabilitation
Diagnostic Radiology
Internal Medicine
General Surgery
Internal Medicine
Diagnostic Radiology
*These referrals represent the top 10 that Dr. Foster has made to other doctors


NAFLD prevalence differs among hispanic subgroups: the Multi-Ethnic Study of Atherosclerosis. - World journal of gastroenterology : WJG
To compare prevalence rates of non-alcoholic fatty liver disease (NAFLD) between Hispanics of Mexican origin and Hispanics of Dominican and Puerto Rican origin.We evaluated prevalence rates of NAFLD between the two largest sub-populations of Hispanics in the United States; Hispanics of Mexican origin and Hispanics of Caribbean origin (Dominican and Puerto Rican), in the multi-ethnic study of atherosclerosis (MESA) cohort. MESA is a large, population based, multi-center cohort study comprised of 6814 healthy Caucasian, African-American, Hispanic, and Asian men and women aged 45-84. We utilized the baseline serum, anthropometric and radiographic measurements obtained between 2000 and 2002. NAFLD was measured via computed tomography scan and was defined as liver/spleen attenuation ratio < 1.There were 788 Hispanic participants included in the study after exclusions. The prevalence of NAFLD was 29% (n = 225). Hispanics of Mexican origin had a significantly higher prevalence of NAFLD (33%), compared to Hispanics of Dominican origin (16%), (P < 0.01) and Hispanics of Puerto Rican origin (18%), (P < 0.01). After controlling for age, sex, BMI, waist circumference, hypertension, serum HDL, triglyceride and CRP level and insulin resistance, Hispanics of Mexican origin remained significantly more likely to have NAFLD than those of Dominican and Puerto Rican origin.United States Hispanics of Mexican origin have a significantly higher prevalence of NAFLD when compared to United States Hispanics of Dominican or Puerto Rican origin after controlling for known risk factors. Care should be taken when performing risk assessment in Hispanic populations not to make assumptions of homogeneity.
The prevalence and clinical correlates of nonalcoholic fatty liver disease (NAFLD) in African Americans: the multiethnic study of atherosclerosis (MESA). - Digestive diseases and sciences
Nonalcoholic fatty liver disease (NAFLD) is the number one cause of liver disease in the United States. The prevalence rates in African Americans (AA), while significantly lower than other ethnic groups with similar known risk factors, have been quoted as high as 24 %. We aim to determine if the presence of NAFLD in African Americans is associated with lower triglyceride and/or higher HDL-c levels and if NAFLD risk factors in African Americans differ from other ethnic groups.A total of 3,056 participants of the Multi Ethnic Study of Atherosclerosis were included in this study. We utilized the baseline serum, anthropometric and radiographic measurements obtained between 2000 and 2002. NAFLD was defined as liver spleen ratio <1 from CT measurements.The prevalence of NAFLD was and 11 % in AA. We found that age, education, triglyceride levels, HDL-c levels, waist circumference and HOMA-IR were independent correlates of NAFLD in this population. Among those with NAFLD, AA had significantly lower triglyceride levels than Hispanics [125 mg/dl (95 % CI 107-143) versus 192 mg/dl (95 % CI 169-215), p < 0.001] and Caucasians [185 mg/dl (95 % CI 161-209), p = 0.001]. Serum HDL-c was significantly higher in AA with NAFLD (47 mg/dl; 95 % CI 45-50) when compared to Hispanics (44 mg/dl; 95 % CI 43-66, p = 0.02) and Caucasians (44 mg/dl; 95 % CI 42-46, p = 0.02) with NAFLD.This study demonstrated that the clinical correlates of NAFLD in African Americans are similar to the correlates of NAFLD in other ethnic groups. Our data also suggests that when evaluating African Americans for NAFLD risk, lower cutoff values should be used to define abnormal triglyceride levels.
Screening high risk individuals for hepatitis B: physician knowledge, attitudes, and beliefs. - Digestive diseases and sciences
Although the overall incidence of hepatitis B virus (HBV) has declined since the introduction of universal vaccine guidelines, the incidence remains elevated in high risk groups. Recent guidelines from the Centers for Disease Control (CDC) have underscored the importance of vaccination against HBV in high risk individuals. However, the incidence of HBV in this group remains elevated, suggesting underuse of vaccinations by healthcare providers.The purpose of this study was to measure practice patterns of HBV vaccination, and identify predictors of vaccination underuse.We created a survey with four vignettes describing patients at high risk for contracting HBV, followed by questions regarding knowledge, attitudes, and beliefs (KAB) of HBV screening and vaccination. A random sample of 1,000 physicians, including internists, family medicine, OB/GYN, gastroenterologists, and experts in HBV epidemiology were surveyed. Regression analysis on composite guideline adherence scores identified KAB profiles that predict scores.On average, responders endorsed 71% of the CDC HBV vaccination guidelines. There were three predictors of diminished screening proclivity: (1) younger provider age (P = 0.028), (2) lower awareness that adult HBV is contracted primarily through heterosexual sex (P = 0.023), and (3) being a provider other than a gastroenterologist (P = 0.009).Respondents endorsed most-but not all-CDC supported HBV screening practices. Lower adherence was predicted by specific and modifiable KAB profiles, and by younger age. Future efforts to improve adherence should target trainees, emphasize the importance of obtaining sexual histories in high risk patients, and inform that HBV is predominantly a heterosexually transmitted infection.
Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. - The American journal of gastroenterology
Nonalcoholic fatty liver disease (NAFLD) is defined as the spectrum of benign fatty liver to necroinflammation and fibrosis. Its prevalence has been found to be as high as 39%. It is estimated that up to 15% of those affected will go on to have progressive liver disease. Currently, there is no proven therapy for NAFLD. In this study, we aim to determine whether statin therapy may be an effective treatment for NAFLD and identify independent predictors of NAFLD.In all, 1,005 men and women, aged 50-70 years were randomized to receive either a daily combination of atorvastatin 20 mg, vitamin C 1 g, and vitamin E 1,000 IU vs. matching placebo, as part of the St Francis Heart Study randomized clinical trial. Liver to spleen (LS) ratios were calculated on 455 subjects with available computed tomography scans performed at baseline and follow-up to determine NAFLD prevalence. Baseline and final LS ratios were compared within treatment groups, and results were compared between the treatment and placebo groups using univariate and multivariate analyses. Mean duration of follow-up was 3.6 years.There were 80 patients with NAFLD at baseline. We identified baseline triglyceride levels (odds ratio (OR)=1.003, P<0.001) and body mass index (OR=0.10, P<0.001) as independent correlates of NAFLD. Treatment with atorvastatin combined with vitamins E and C significantly reduced the odds of NAFLD at the end of follow-up, 70 vs. 34% (OR=0.29, P<0.001).In conclusion, atorvastatin 20 mg combined with vitamins C and E is effective in reducing the odds of having hepatic steatosis by 71% in healthy individuals with NAFLD at baseline after 4 years of active therapy.

Map & Directions

49 Jesse Hill Jr Dr Se Rm437 Atlanta, GA 30303
View Directions In Google Maps

Nearby Doctors

49 Jesse Hill Jr Dr Se
Atlanta, GA 30303
404 166-6673
69 Jesse Hill Jr Dr Se Glenn Memorial Bld, 3Rd Floor
Atlanta, GA 30303
412 518-8745
80 Jesse Hill Jr Dr Se
Atlanta, GA 30303
404 164-4570
75 Marietta St Nw Suite 100
Atlanta, GA 30303
404 770-0868
99 Jesse Hill Jr Drive, Se
Atlanta, GA 30303
404 131-1201
229 Peachtree St Suite 206
Atlanta, GA 30303
404 227-7913
100 Edgewood Ave Ne
Atlanta, GA 30303
404 269-9304
69 Jesse Hill Jr Dr Se
Atlanta, GA 30303
404 561-1497
69 Jesse Hill Jr Dr Se
Atlanta, GA 30303
404 861-1000
80 Jesse Hill Jr Dr
Atlanta, GA 30303
404 166-6456